RxDoctor Payments Data

Olivia Neeley, PA

Medical · Statesboro, GANPI 1114340411

Payments from drug & device makers

$3,212in general payments, 2019–2025

Across 165 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$943
  • Axsome Therapeutics, Inc.$334
  • Tris Pharma Inc$325
  • Otsuka America Pharmaceutical, Inc.$220
  • Vanda Pharmaceuticals Inc.$214
  • Takeda Pharmaceuticals U.S.A., Inc.$178
  • plus $999 from 12 others

What the payments were for

  • Food & beverage$3,212100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,212 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$5,789
Medicare patients
30
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole18$27,518
TrintellixVortioxetine Hydrobromide24$12,267
Aripiprazole52$1,316
Vilazodone Hcl14$666
Buspirone Hcl45$596
Bupropion XlBupropion Hcl30$424
Duloxetine Hcl23$344
Lamotrigine49$275
Risperidone22$255
Trazodone Hcl42$239
Venlafaxine Hcl ErVenlafaxine Hcl22$219
Citalopram HbrCitalopram Hydrobromide26$207
Gabapentin23$190
Fluoxetine Hcl18$171
Hydroxyzine Hcl13$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$220$27,51818 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$178$12,26724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.

Other medical in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →